Basilea Pharmaceutica Ltd. Logo

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.

Thursday, November 05. 2015
  • Tumor check point controller BAL101553 demonstrates inhibitory activity on tumor stem cell self-renewal and invasion in models of brain cancer
  • Loss of glioblastoma stem cell properties induced by BAL101553 correlates with EB1 expression levels in vitro and in animal models
Friday, October 23. 2015
Basel, Switzerland, October 23, 2015 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the orphan drug designation of the antifungal isavuconazole for the treatment of invasive aspergillosis and mucormycosis has been maintained. Accordingly, isavuconazole will benefit from ten years of market exclusivity associated with orphan medicinal product status in the European Union.
Friday, October 16. 2015
  • Basilea seeks access to U.S. public equity market
  • The offering is intended to:
    • increase liquidity, visibility and coverage for Basilea shares
    • facilitate Basilea's participation in ceftobiprole phase 3 development program to gain U.S. regulatory approval
    • support commercialization activities of ceftobiprole and
      isavuconazole, and
    • further advance Basilea's research and development projects
Friday, October 16. 2015
  • Basilea's second anti-infective product approved in Europe, providing potential commercial synergy with Zevtera® (ceftobiprole)

Infectious Diseases
Society of America